专用与非专用静脉支架治疗髂股静脉梗阻12个月通畅率的系统评价与荟萃分析
该系统评价与荟萃分析纳入49项研究共5154例患者,比较专用与非专用静脉支架治疗髂股静脉梗阻的1年通畅率。非血栓性髂静脉病变、急性深静脉血栓和血栓后综合征组的1年一期通畅率分别为96%、91%、77%-78%,专用与非专用支架在非血栓性髂静脉病变和血栓后综合征患者中1年通畅率相当,但研究间存在显著异质性,亟需标准化评价标准。
要点
- 纳入49项研究5154例患者,非血栓性髂静脉病变1431例、深静脉血栓950例、血栓后综合征2773例。
- 1年一期通畅率:非血栓性髂静脉病变96%,深静脉血栓91%,血栓后综合征77%-78%。
- 专用与非专用静脉支架在非血栓性髂静脉病变和血栓后综合征患者中1年通畅率相当。
核心结论
- 第一代专用静脉支架在非血栓性髂静脉病变和血栓后综合征患者中1年通畅率和临床结局与非专用技术相当。
- 研究间存在显著异质性,亟需标准化标准来报告深静脉支架植入患者的结局。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE和EMBASE,纳入49项评估静脉支架置入有效性的研究,共5154例患者(非血栓性髂静脉病变1431例、深静脉血栓950例、血栓后综合征2773例)。
主要发现
- 技术成功率各组相当(97%-100%),无围手术期死亡,轻微出血高达5%,大出血0.5%,血栓后综合征患者中55%出现短暂背痛。
- 1年一期通畅率和累积通畅率:非血栓性髂静脉病变96%和100%;深静脉血栓91%和97%;血栓后综合征(支架位于韧带上方)77%和94%;血栓后综合征(支架跨越韧带)78%和94%。
- 急性深静脉血栓患者中专用与非专用静脉支架的通畅结局数据不足,无法比较;非血栓性髂静脉病变和血栓后综合征患者中1年支架通畅率相当。
- 静脉跛行改善率:血栓后综合征患者83%,非血栓性髂静脉病变患者90%;溃疡愈合率:血栓后综合征患者80%,非血栓性髂静脉病变患者32%。
关键数值与推荐
- 技术成功率各组均为97%-100%。
- 1年一期通畅率:非血栓性髂静脉病变96%,深静脉血栓91%,血栓后综合征(支架位于韧带上方)77%,血栓后综合征(支架跨越韧带)78%。
- 1年累积通畅率:非血栓性髂静脉病变100%,深静脉血栓97%,血栓后综合征(支架位于韧带上方)94%,血栓后综合征(支架跨越韧带)94%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 报告血栓后综合征患者结局的研究间存在显著异质性。
- 急性深静脉血栓患者中专用与非专用静脉支架的通畅结局数据不足,无法比较。
- 干预前后症状测量中验证工具的使用不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular stenting of the deep venous system has been proposed as a method to treat patients with symptomatic iliofemoral outflow obstruction. The purpose of this systematic review and meta-analysis was to compare the effectiveness of this treatment at 1-year following the development of dedicated venous stents. METHOD AND RESULTS: We searched MEDLINE and EMBASE for studies evaluating the effectiveness of venous stent placement. Data were extracted by disease pathogenesis: non-thrombotic iliac vein lesions (NIVL), acute thrombotic (DVT), or post-thrombotic syndrome (PTS). Main outcomes included technical success, stent patency at 1 year and symptom relief. A total of 49 studies reporting outcomes in 5154 patients (NIVL, 1431; DVT, 950; PTS, 2773) were included in the meta-analysis. Technical success rates were comparable among groups (97%-100%). There were no periprocedural deaths. Minor bleeding was reported in up to 5% of patients and major bleeding in 0.5% upon intervention. Transient back pain was noted in 55% of PTS patients following intervention. There was significant heterogeneity between studies reporting outcomes in PTS patients. Primary and cumulative patency at 1 year was: NIVL-96% and 100%; DVT-91% and 97%; PTS (stents above the ligament)-77% and 94%, and; PTS (stents across the ligament)-78% and 94%. There were insufficient data to compare patency outcomes of dedicated and nondedicated venous stents in patients with acute DVT. In NIVL and PTS patients, stent patency was comparable at 1 year. There was inconsistency in the use of validated tools for the measurement of symptoms before and after intervention. When reported, venous claudication, improved in 83% of PTS patients and 90% of NIVL patients, and ulcer healing occurred in 80% of PTS patients and 32% of NIVL patients. CONCLUSIONS: The first generation of dedicated venous stents perform comparably in terms of patency and clinical outcomes to non-dedicated technologies at 1 year for the treatment of patients with NIVL and PTS. However, significant heterogeneity exists between studies and standardized criteria are urgently needed to report outcomes in patients undergoing deep venous stenting.
引用
- Majeed GM, Lodhia K, Carter J, et al. A Systematic Review and Meta-Analysis of 12-Month Patency After Intervention for Iliofemoral Obstruction Using Dedicated or Non-Dedicated Venous Stents. J Endovasc Ther. 2021. PMID: 34758673. doi:10.1177/15266028211057085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。